Highlights MediWound Ltd.

Equities

MDWD

IL0011316309

Real-time Estimate Cboe BZX Other stock markets 03:26:46 2024-04-29 pm EDT			5-day change	1st Jan Change
19.1 ^USD	+4.74%		+21.61%	+88.45%

Mar. 21	MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026	CI
Mar. 21	Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026	Mar. 21	CI
MediWound Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Earnings Flash (MDWD) MEDIWOUND Posts Q4 Revenue $5.3M, vs. Street Est of $5.3M	Mar. 21	MT
MediWound Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study	Feb. 12	CI
MediWound's NexoBrid Application to Include Pediatric Patients Accepted for Review by FDA	Jan. 09	MT
Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns	Jan. 09	CI
Mediwound Ltd. Secures Additional U.S. Department of Defense Funding to Advance Nexobrid® Development for the U.S. Army	Dec. 28	CI
Mediwound Ltd. Announces Publication of Escharex Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads	Dec. 21	CI
Earnings Flash (MDWD) MEDIWOUND Reports Q3 Revenue $4.8M, vs. Street Est of $4.8M	Nov. 21	MT
MediWound Wins European Agency Approval for NexoBrid Expansion to All Age Groups in Deep Thermal Burn Cases	Nov. 13	MT
MediWound Ltd Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients	Nov. 13	CI
MediWound Ltd. Announces Collaboration with PolyMedics Innovations for NexoBrid Distribution in Europe	Nov. 08	CI
MediWound Collaborates With 3M Unit on Drug Candidate EscharEx Late-Stage Study	23-10-11	MT
MediWound Ltd. Deploys NexoBrid® for Emergency Supply	23-10-09	CI
MediWound Receives $6.5 Million Funding From Defense Department to Develop Burn Treatment for US Army	23-09-26	MT
MediWound Ltd. Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army	23-09-26	CI
MediWound Launches NexoBrid for Treatment of Severe Thermal Burns	23-09-21	MT
MediWound Ltd. Announces U.S. Commercial Availability of NexoBrid®? for the Treatment of Severe Thermal Burns in Adults	23-09-21	CI
MediWound Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MediWound Ltd.

Equities

MDWD

IL0011316309

Highlights

Filters